Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cognizant Technology Solutions Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Cognizant Technology Solutions Corp trades at $58.83 (market cap $26.27B). The key difference: Cognizant Technology Solutions Corp is far larger — about 30.4× Amphastar Pharmaceuticals Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.26% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CTSH | |
|---|---|---|
Market Cap | $863.95M | $26.27B |
Sector | Health | Technology |
52-Week High | $30.81 | $86.70 |
52-Week Low | $16.87 | $38.73 |
Enterprise Value | $1.26B | $27.31B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
CTSH trades at $57.67, up 1.37% with a bullish technical signal. Recent Q2 2026 earnings missed EPS estimates at $1.37 versus $1.38 expected, though revenues beat. The company maintains solid fundamentals with a P/E of 12.37 and ROE of 14.92%, supported by strong cash flow from operations of $2.88B in 2025. AI initiatives, including the new EMEA AI Unit, highlight growth efforts amid cautious client spending.
Outlook is mixed: valuation appears attractive with upside to the $59.92 consensus target, but risks include macroeconomic pressures on IT spending and competitive disruption from AI. Earnings consistency and AI adoption execution are critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
